Aura Biosciences (AURA) to Release Quarterly Earnings on Wednesday

Aura Biosciences (NASDAQ:AURA) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Aura Biosciences Stock Performance

Shares of NASDAQ AURA opened at $7.42 on Wednesday. The firm has a market cap of $370.64 million, a price-to-earnings ratio of -4.29 and a beta of 0.30. The business’s 50-day simple moving average is $7.68 and its 200-day simple moving average is $8.67. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 23,045 shares of company stock valued at $177,242 in the last 90 days. 5.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.